cabazitaxel / Generic mfg. - LARVOL DELTA

Antitumor effects of coffee diterpenes, kahweol acetate and cafestol, on taxane-resistant and neuroendocrine prostate cancer cells (AACR 2026) - "We aimed to investigate the antitumor potential and underlying mechanisms of kahweol acetate and cafestol in these refractory prostate cancer models. We used docetaxel-resistant (DU145-TxR, PC-3-TxR) and cabazitaxel-resistant (DU145-TxR/CxR, PC-3-TxR/CxR) prostate cancer cell lines, which were established from their respective parental DU145 and PC-3 cells. Kahweol acetate and cafestol exert strong antitumor effects in taxane-resistant and neuroendocrine prostate cancer cells through synergistic induction of apoptosis and inhibition of EMT. Given their efficacy at clinically achievable concentrations, these coffee-derived diterpenes represent promising candidates for novel therapeutic approaches in treatment-resistant prostate cancer."

IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Genitourinary Neuroendocrine Carcinoma • Oncology • Prostate Cancer • Solid Tumor • BCL2 • BCL2L1 • CASP3 • SNAI2

Plasma cell-free DNA nucleosome footprints in metastatic castration-resistant prostate cancer (mCRPC) (AACR 2026) - "Herein, we quantify nucleosome occupancy at binding sites for hundreds of TFs, evaluating the clinical utility of these functional readouts in plasma taken from subjects treated on the CARD prospective randomized trial of cabazitaxel (CAB) vs second androgen receptor pathway inhibitor (ARPI). Plasma cfDNA lpWGS (median coverage ~1.6x) was used to infer nucleosome footprints at TF binding sites (TFBS) of 682 TFs... Evaluating nucleosome footprints at TFBS using lpWGS is a robust approach that identifies valuable functional biomarkers of drug sensitivity. Such studies offer the opportunity to interrogate disease progression through serial clinical samples, where phenotype profiling is otherwise unfeasible."

Cell-free DNA • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • E2F1 • FOXP1 • GRHL2 • MYCN • NKX3-1

C3NIRA: Randomized phase II study of carboplatin-cabazitaxel-cetrelimab (anti-PD-1) induction followed by niraparib +/- cetrelimab maintenance in men with aggressive variant prostate cancers (AVPC). (ASCO 2025) - P2 | "Most were White/non-Hispanic (78%) and had not received prior docetaxel (58%). A subset of men with AVPC derive meaningful benefit from the addition of anti-PD-1 to PARP inhibitor maintenance following platinum-taxane-anti-PD-1 induction. Ongoing correlates aim to identify biomarkers to select patients for this treatment strategy and reveal candidate mechanisms of resistance to guide future therapeutic combinations."

Clinical • IO biomarker • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • FOXP3

Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 Study. (PubMed, Clin Cancer Res) - "Cabazitaxel and carboplatin followed by abiraterone, together with ADT, was feasible, safe, and efficacious in patients with high-volume mCSPC, and warrants further study in larger randomized trials."

Journal • P2 data • Fatigue • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • HRD

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) (clinicaltrials.gov) - P3 | N=675 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting

Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel. (PubMed, Int J Clin Oncol) - "The mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CRP

[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. (PubMed, Lancet) - P2 | "[Lu]Lu-PSMA-617 compared with cabazitaxel in men with metastatic castration-resistant prostate cancer led to a higher PSA response and fewer grade 3 or 4 adverse events. [Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel."

Clinical • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603). (ASCO 2025) - P2 | "Here, we explored CH in the TheraP trial randomizing participants (pts) with docetaxel-refractory mCRPC to cabazitaxel or 177Lu-PSMA-617 (NCT03392428). 177Lu-PSMA-617 was associated with a greater number of new CH mutations, especially in DNA damage repair genes, compared to cabazitaxel. Whilst the clinical relevance of this finding in a population of patients with heavily-treated mCRPC is unclear, CH emergence and expansion may have implications as radioligand therapy is used as an earlier line of therapy."

Clinical • Metastases • P2 data • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ASXL1 • CHEK2 • DNMT3A • PPM1D • TET2

Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial. (ASCO-GU 2026) - P3 | "Cabazitaxel does not improve cPFS in very-high risk localized prostate cancer. With very few prostate cancer-related deaths observed during the first decade, data from PEACE-2 challenge our current definition of very-high risk localized prostate cancer, especially when defined using modern imaging."

Clinical • Late-breaking abstract • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Apr 2030 ➔ Mar 2028

Trial completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

CABA-GCT: A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors (clinicaltrials.gov) - P2 | N=34 | Completed | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Unknown status ➔ Completed

Trial completion • Germ Cell Tumors • Oncology • Testicular Non-seminoma

Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. (PubMed, Nat Med) - P2 | "We anticipate our ctDNA fraction-aware analytical framework will aid future precision management strategies for [¹⁷⁷Lu]Lu-PSMA-617 and other PSMA-targeted therapeutics. ClinicalTrials.gov identifier: NCT03392428 ."

Circulating tumor DNA • Journal • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ATM • FOLH1 • PTEN

Real-world effectiveness of systemic therapies after 177Lu]Lu-PSMA-617 (177Lu-PSMA-617) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis. (ASCO-GU 2026) - "Systemic therapies included ARPIs (abiraterone, enzalutamide, darolutamide, apalutamide); chemotherapy (cabazitaxel, docetaxel, carboplatin, cisplatin, etoposide, mitoxantrone); immunotherapy (pembrolizumab, sipuleucel-T); poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, talazoparib, rucaparib); and radium-223. In this real-world analysis, meaningful clinical responses were observed in a subset of patients who received subsequent systemic therapies after 177Lu-PSMA-617."

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study. (ASCO-GU 2026) - P1 | "Pts were heavily pretreated with a median of 3 (range 1–9) prior therapies, including ARPI (100%), DOCE (43.1%), cabazitaxel (21.6%), Lutetium-177 vipivotide tetraxetan (19.6%). PAS was readily combinable with DOCE, demonstrating a safety profile consistent with DOCE alone, no CRS, and promising anti-tumor activity in heavily pretreated patients post-ARPI/taxanes. A confirmatory phase 3 trial is planned."

Clinical • First-in-human • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KLK2

Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study. (ASCO 2025) - P | "Prior treatments included abiraterone (48% of pts), enzalutamide (39%), docetaxel (39%), and cabazitaxel (9%). This real-world safety analysis of pts with mCRPC is the longest follow-up of a radiopharmaceutical reported to date and supports the well-established favorable safety profile of Ra-223. The incidence of SPMs was low. The rate of fracture was low, especially in the presence of BHAs."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Musculoskeletal Diseases • Oncology • Orthopedics • Prostate Cancer • Solid Tumor

REAL-WORLD COMPARATIVE EFFECTIVENESS OF LUTETIUM-177-PSMA-617 VERSUS CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (ISPOR 2026) - "Patients were required to have prior treatment with docetaxel and one or more ARPI (abiraterone, apalutamide, enzalutamide, or darolutamide) before index treatment. In this real-world analysis of mCRPC patients with prior docetaxel and ARPI exposure, Lu-PSMA demonstrated superior OS and PFS compared to cabazitaxel. These findings support Lu-PSMA's clinical benefit in this population and warrant further investigation in chemotherapy-naïve patients, given its most recent pre-chemotherapy approval."

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2026) - "Background: LuPSMA and cabazitaxel are both standard of care options for men with PSMA-positive mCRPC post docetaxel. Cabazitaxel demonstrates modest activity following LuPSMA. While PSA50 were comparable to historical data, the poor survival outcomes suggest reduced taxane sensitivity. Patients who responded to LuPSMA trended to also have better responses with cabazitaxel."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Allergy to cabazitaxel: Cross-reactivity between taxanes. (PubMed, Allergol Immunopathol (Madr)) - "His treatment was started with docetaxel, receiving five cycles with good tolerance, after which he received hormonal treatment. After the infusion of 11 mL, the patient presented pharyngeal obstruction with dyspnoea, facial erythema, genital pruritus, and cervical pain that required treatment with intramuscular epinephrine. The results of the allergy study were not concordant with clinical presentation and confirmed the poor predictive value of taxane skin tests."

Journal • Allergy • Dermatology • Genito-urinary Cancer • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Musculoskeletal Pain • Oncology • Pain • Prostate Cancer • Pruritus • Pulmonary Disease • Solid Tumor • IL6

Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer. (ASCO-GU 2026) - "Background: Survival expectations for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving late-line therapies have historically been defined by trials conducted prior to the approval of lutetium-177 vipivotide tetraxetan (Lu177)...Post-taxane was defined as prior receipt of docetaxel or cabazitaxel in mCRPC...The most common regimens were cabazitaxel monotherapy (19%), cabazitaxel and carboplatin (12%), and enzalutamide monotherapy (9%)... Among the mCRPC pts receiving subsequent therapy after Lu177, tx selection was heterogeneous and primarily chemotherapy-based. The short tx duration and limited survival highlights more effective therapies after Lu177 tx are needed to improve outcomes in mCRPC. Baseline disease characteristics at initiation of post-Lu177 tx and survival."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Triplet therapy with ADT, darolutamide, and biweekly docetaxel for high-risk metastatic castration-sensitive prostate cancer (TRIC): An open-label, single-arm phase II clinical trial. (ASCO-GU 2026) - "Clinical Trial Registry Number: CRB4180005. The primary endpoint is PSA response rate, defined as a ≥95% PSA decline from baseline at 3 and 6 months. Secondary endpoints include OS, time to castration resistance, radiographic and clinical progression-free survival, undetectable PSA rate, time to neuroendocrine and double-negative prostate cancer, symptomatic skeletal event (SSE)-free survival, time to first SSE, pain progression, subsequent therapy, cabazitaxel use, performance status decline, opioid use ≥7 days, safety, adverse events, and correlations between serum CCL2/CCL5 levels and treatment response."

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • CCL2

Phase 1/2 OMAHA-U01 substudy 01A: Oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2026) - P1/2 | "Participants will be randomly assigned 1:1:1:1 to receive opevesostat 5 mg PO BID, opevesostat 5 mg PO BID plus olaparib (RP2D), opevesostat 5 mg PO BID plus docetaxel (RP2D), or opevesostat 5 mg PO BID plus cabazitaxel (RP2D). Secondary end points include objective response rate and radiographic progression-free survival per PCWG-modified RECIST v1.1 by blinded independent central review (BICR), overall survival, duration of response by BICR, time to first subsequent anticancer therapy, and time to pain progression. The predefined eligibility cap for pts with AR-LBDm-negative status has been reached, and the study is currently only enrolling pts with AR-LBDm-positive status."

Combination therapy • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

CYP11A1 INHIBITOR OPEVESOSTAT ALONE OR IN COMBINATION WITH OTHER THERAPIES FOR PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE PHASE 1/2 OMAHA-01A SUBSTUDY (SUO 2025) - P1/2 | "In the efficacy phase, participants will be randomized 1:1:1:1 to receive opevesostat alone (5 mg PO BID; N≤100), or in combination with olaparib, docetaxel or cabazitaxel at the RP2D (~40 participants each). Secondary end points include ORR, DOR and radiographic PFS per PCWG-modified RECIST v1.1, and OS. "

Combination therapy • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (clinicaltrialsregister.eu) - P1/2 | N=76 | Recruiting | Sponsor: Novartis Pharma AG | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (clinicaltrialsregister.eu) - P1/2 | N=76 | Not yet recruiting | Sponsor: Novartis Pharma AG

New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

20230239: Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer (clinicaltrialsregister.eu) - P2/3 | N=295 | Recruiting | Sponsor: Amgen Inc.

New P2/3 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor